Key result
Probucol fails to significantly reduce cerebrocardiovascular events versus control in Asian CAD patients.
Why the study?
The effect of probucol on cerebrocardiovascular events and carotid intima-media thickness in Asian patients with coronary artery disease was uncertain.
Does probucol reduce major adverse cerebrocardiovascular events in Asian patients with coronary artery disease?
Population
1,025 Japanese, Korean, and Chinese patients with coronary artery disease
Comparison
Probucol vs control group
Design
Integrated analysis of two randomized controlled trials (PROSPECTIVE and IMPACT)
Authors
Loading...
Probucol shows a nonsignificant trend toward fewer events without IMT benefit; leaves open efficacy for secondary prevention in Asian CAD patients.
Meta-Analysis (n=1,025)
Randomized
Yes
Does probucol reduce major adverse cerebrocardiovascular events in Asian patients with coronary artery disease?
Hazard Ratio: 0.67 (95% CI 0.44–1.03)
Absolute Event Rate: 1.98% vs 2.92%
p-value: p=0.052
Probucol demonstrated a marginal, non-significant trend toward reducing cerebrocardiovascular events in Asian patients with CAD, though it appeared safe and showed benefit in a subgroup with greater HDL-C reductions.
Arai et al. (2021) conducted a meta-analysis in Coronary artery disease (n=1,025). Probucol vs. Control (statin alone) was evaluated on Time to the first major adverse cerebrocardiovascular event (HR 0.67, 95% CI 0.44-1.03, p=0.052). Probucol showed a marginal, non-significant tendency to reduce cerebrocardiovascular events compared to control in Asian patients with coronary artery disease (HR 0.67).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: